CancerDrs

Breast Cancer clinical trials in Michigan

40 actively recruiting breast cancer trials at 57 sites across Michigan.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Michigan:
  • Hickman Cancer Center — Adrian, Michigan
  • MyMichigan Medical Center Gratiot — Alma, Michigan
  • MyMichigan Medical Center Alpena — Alpena, Michigan
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Michigan:
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Bronson Battle Creek — Battle Creek, Michigan
  • McLaren Cancer Institute-Bay City — Bay City, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Michigan:
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Bronson Battle Creek — Battle Creek, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
  • University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
  • Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Michigan:
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
  • Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
  • Henry Ford Macomb Hospital-Clinton Township — Clinton Township, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…

Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Michigan:
  • Henry Ford Health System — Detroit, Michigan
  • Cancer and Hematology Centers of Western Michigan — Grand Rapids, Michigan
  • Ascension — Grosse Pointe Woods, Michigan
  • William Beaumont Hospital — Royal Oak, Michigan
  • Ascension Providence Hospital Southfield Cancer Center — Southfield, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…

Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Michigan:
  • The Cancer & Hematology Centers — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Michigan:
  • Research Site — Detroit, Michigan
  • Research Site — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Michigan:
  • Henry Ford Hospital — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Michigan:
  • Henry Ford Health System — Detroit, Michigan
  • Cancer & Hematology Centers of Western Michigan — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Michigan:
  • Wayne State University/Karmanos Cancer Institute — Detroit, Michigan
  • Weisberg Cancer Treatment Center — Farmington Hills, Michigan
  • McLaren Cancer Institute-Flint — Flint, Michigan
  • Karmanos Cancer Institute at McLaren Greater Lansing — Lansing, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…

Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in Michigan:
  • Cancer and Hematology Centers of Western Michigan — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …

Sponsor: Celcuity Inc
NCT ID: NCT06757634
Sites in Michigan:
  • Henry Ford Health System — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Michigan:
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Bronson Battle Creek — Battle Creek, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
  • Trinity Health Medical Center - Brighton — Brighton, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…

Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Michigan:
  • University of Michigan — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

Sponsor: Oana Danciu
NCT ID: NCT05467891
Sites in Michigan:
  • University of Michigan Health System — Ann Arbor, Michigan
  • University of Michigan Health-West — Wyoming, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal gro…

Sponsor: Hummingbird Bioscience
NCT ID: NCT06956690
Sites in Michigan:
  • Research Site — Farmington Hills, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer. Tamoxifen is a selec…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06195306
Sites in Michigan:
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

This phase II trial compares leuprolide to goserelin for reducing estrogen production by the ovaries in pre- or peri-menopausal women with breast cancer. Estrogen can cause the growth of breast cancer cells. Both leuprolide and goserelin l…

Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT07158021
Sites in Michigan:
  • University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Michigan:
  • University of Michigan — Ann Arbor, Michigan
  • Henry Ford Cancer Institute — Detroit, Michigan
  • START - Midwest Cancer Research Center — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive …

Sponsor: Eli Lilly and Company
NCT ID: NCT07114601
Sites in Michigan:
  • Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
  • BAMF Health Inc. — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment …

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT05508906
Sites in Michigan:
  • Henry Ford Health — Detroit, Michigan
View on ClinicalTrials.gov →

Showing 25 of 40 trials with sites in Michigan. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17